EHA 2022 | The current state of the art in HR-MDS and the need to improve treatment approaches
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares some insights into current state of the art treatment approaches in high-risk myelodysplastic syndromes (HR-MDS) and the importance of upcoming clinical trials aiming to improve treatment options for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Receiving grant support, paid to GWT-TUD, from Amgen, lecture fees, grant support, paid to the University of Leipzig, fees for serving on a steering committee, consulting fees, and travel support from Celgene, grant support, paid to GWT-TUD, from Janssen Biotech, grant support, paid to University Dresden, from Merck and Novartis, and lecture fees from Novartis.
